GALT

In the past six months, Galectin Therapeutics experienced several stock events: positive Type C meeting results with the FDA in June 2026 clarified a path toward full approval for belapectin's Phase III MASH cirrhosis program, leading to an 11% stock surge. In August 2026, the company converted $105.8 million in debt to equity, strengthening its balance sheet. Financial results reported in May and August 2026 included a wider Q2 loss due to higher expenses, negatively impacting the stock. In March 2026, GALT was upgraded to a Zacks Rank #2 (Buy), and HC Wainwright issued earnings estimates, while short interest increased by 27.0%. The company also presented new analyses at EASL 2026 in May, published NAVIGATE Phase 2b trial results, and was scheduled to present at the H.C. Wainwright 28th Annual Global Investment Conference in September 2026.